Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeoVax Labs, Inc.GOVX · Entity 8419 | Director · CSO Emeritus | December 17, 2018 | December 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeoVax Labs, Inc.
Report date December 17, 2018 · Filed December 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Purchase OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.03 · Expires 2028-12-17 | Direct | 600,000 |
Reported balance
After 2018-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-17 · Grant · Acquired 600,000 · Balance 600,000 F1: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2018 Filed Dec 19, 2018 20:38 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 600,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001437749-18-022295 · rdgdoc.xml · derivative · entry 1 ROBINSON HARRIET L · CIK 0001377780 · Director · CSO Emeritus 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2028-12-17 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 16:25 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 450,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001437749-17-021097 · rdgdoc.xml · derivative · entry 1 ROBINSON HARRIET L · CIK 0001377780 · Director · CSO Emeritus 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-12-20 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 21:31 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantCommon Stock Purchase Option · Derivative | 262,200 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001437749-16-043429 · rdgdoc.xml · derivative · entry 1 ROBINSON HARRIET L · CIK 0001377780 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,200 Underlying: Common Stock · 262,200 shares Expires 2026-12-13 F1 · derivative.exercise_date: Stock option becomes exercisable in three equal annual installments of the first three anniversary dates of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.